Oct. 20 Quick Takes: Perceptive’s LianBio aiming for $325M IPO

China-focused cross-border biotech LianBio proposed terms for a NASDAQ IPO that could value the company in the $1.7 billion range. According to an updated prospectus, LianBio is hoping to sell 20.3 million ADSs at $15-$17, which would raise $325 million at the $16 midpoint. The biotech has nine clinical assets, including programs for cardio-renal, oncology, ophthalmic, inflammatory and respiratory indications. Underwriters are Goldman Sachs, Jefferies, BofA Securities and Raymond James.

ShouTi Inc. emerged from stealth with a $100 million series B round and a platform to develop oral small molecules to replace GPCR-targeting biologics and peptides for chronic cardiovascular, metabolic and pulmonary diseases. The company’s lead program is in Phase I testing for pulmonary arterial hypertension. ...